title: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
abstract: OBJECTIVE
  Identifying suitable markers of biologic activity is important when assessing novel compounds such as angiogenesis inhibitors to optimize the dose and schedule of therapy. Here we present the pharmacodynamic response to acute dosing of AG-013736 measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
  
  
  METHODS
  Thirty-six patients with advanced solid tumors were treated with various doses of AG-013736. In addition to standard measures of objective disease response and pharmacokinetic analysis, DCE-MRI scans were acquired at baseline and repeated at cycle 1--day 2 after the scheduled morning dose of the AG-013736 in 26 patients. Indicators of a vascular response, such as the volume transfer constant (K(trans)) and initial area under the curve (IAUC), were calculated to assess the effect of treatment on tumor vascular function.
  
  
  RESULTS
  Evaluable vascular response data were obtained in 17 (65%) of 26 patients. A linear correlation was found in which the percentage change from baseline to day 2 in K(trans) and IAUC was inversely proportional to AG-013736 exposure. Using a conservative a priori assumption that a > or = 50% decrease in K(trans) was indicative of an objective vascular response, a 50% decrease in K(trans) was achieved and corresponded to a plasma AUC(0-24) of > 200 ng . h/mL.
  
  
  CONCLUSIONS
  A sufficient decrease in tumor vascular parameters was observed at a dose chosen for additional phase II testing by conventional toxicity criteria. In addition, the day 2 vascular response measured using DCE-MRI seems to be a useful indicator of drug pharmacology, and additional research is needed to determine if it is a suitable marker for predicting clinical activity.
authors: University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA.
authors: Glenn
authors: G
authors: Liu
authors: Hope S
authors: HS
authors: Rugo
authors: George
authors: G
authors: Wilding
authors: Teresa M
authors: TM
authors: McShane
authors: Jeffrey L
authors: JL
authors: Evelhoch
authors: Chaan
authors: C
authors: Ng
authors: Edward
authors: E
authors: Jackson
authors: Frederick
authors: F
authors: Kelcz
authors: Benjamin M
authors: BM
authors: Yeh
authors: Fred T
authors: FT
authors: Lee
authors: Chusilp
authors: C
authors: Charnsangavej
authors: John W
authors: JW
authors: Park
authors: Edward A
authors: EA
authors: Ashton
authors: Heidi M
authors: HM
authors: Steinfeldt
authors: Yazdi K
authors: YK
authors: Pithavala
authors: Steven D
authors: SD
authors: Reich
authors: Roy S
authors: RS
authors: Herbst
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019540:Area Under Curve; D003287:Contrast Media / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D019786:Gadolinium DTPA